TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01140984
Drug: Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
Study: NCT01873079
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00185211
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
Study: NCT00185211
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
Study: NCT01305317
Drug: Lipitor
Normalized name: Lipitor
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg daily for 6 months
Study: NCT04304157
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
Study: NCT00265798
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03122301
Drug: Stellate Ganglion Block injection with bupivicaine
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Study: NCT03122301
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sham injection with saline
Study: NCT00973037
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20mg qd
Study: NCT03526887
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg, Q3W
Study: NCT04215146
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
Study: NCT04215146
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
Study: NCT00066807
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Study: NCT00066807
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Study: NCT00066807
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
Study: NCT01172275
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
Study: NCT04206813
Drug: Gardasil 9 2 dose regimen
Normalized name: Gardasil 9
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 2-dose regimen of Gardasil 9 at 0 and 6 months
Study: NCT04206813
Drug: Gardasil 9 3 dose regimen
Normalized name: Gardasil 9
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
Study: NCT04206813
Drug: Gardasil 9 rescue dose
Normalized name: Gardasil 9
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A rescue dose of Gardasil 9 will be given at 12 months
Study: NCT01943409
Drug: Intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: soybean oil-based lipid emulsion
Study: NCT01943409
Drug: ClinOleic
Normalized name: linoleate
DrugBank: Cholesteryl Linoleate (DB02092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: olive oil-based lipid emulsion
Study: NCT03457493
Drug: DPA-714 Metabolite Analysis
Normalized name: DPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.
Study: NCT04640545
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab Injection will be administered by intravenously (Q2W) by the fixed dose of 3 mg/kg .
Study: NCT00273507
Drug: Carboplatin and Paclitaxel
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00209651
Drug: TS-1
Normalized name: CTS-1027
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.
Study: NCT04640545
Drug: Axitinib Tablets
Normalized name: Axitinib Tablets
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib Tablets 5mg and Axitinib Tablets 1mg(On-demand administration)
Study: NCT03333616
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
Study: NCT03333616
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
Study: NCT05270421
Drug: Furosemide 40 mg
Normalized name: furosemide 40 MG
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard ESWL + Furosemide 40 mg
Study: NCT00005851
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00005851
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT00005851
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT02489903
Drug: RRx-001
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02489903
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02489903
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02489903
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02489903
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02489903
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02489903
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02489903
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02489903
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02489903
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02489903
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00046111
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A topoisomerase I inhibitor used for ovarian and lung cancer treatment
Study: NCT00667420
Drug: panitumumab, epirubicin, oxaliplatin, xeloda
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pilot study
Study: NCT00005960
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00989690
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00989690
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00989690
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03940326
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam with initial dose of 500 mg per 12 hours which will be increased 500 mg/week to target dose of 2000 mg/day and the dose could be increased to 3000 mg/day if seizures recurred
Study: NCT03940326
Drug: Valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium valproate with initial dose of 500 mg/day which will be increased 500 mg/week to target dose of 1500 mg/day and the dose could be increased to 2000 mg/d if seizures recurred.
Study: NCT00495131
Drug: Pegylated interferon alfa-2a plus ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
Study: NCT00495131
Drug: Pegylated interferon alfa-2a plus ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
Study: NCT01041729
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
Study: NCT00644748
Drug: gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg
Study: NCT04552730
Drug: Cenegermin-Bkbj
Normalized name: cenegermin-bkbj
DrugBank: Cenegermin (DB13926)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Topical Cenegermin-bkbj 6 times per day for 8 weeks.
Study: NCT00425633
Drug: Homeopathic Potassium Dichromate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 pellets under tongue q12h until extubation
Study: NCT00296803
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02818491
Drug: Dexamethasone 1 mg
Normalized name: dexamethasone 1 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 1 mg in 2 mls
Study: NCT02818491
Drug: Dexamethasone 2 mg
Normalized name: dexamethasone 2 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 2 mg in 2 mls
Study: NCT02818491
Drug: Dexamethasone 3 mg
Normalized name: dexamethasone 3 MG/ML
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 3 mg in 2 mls
Study: NCT02818491
Drug: Dexamethasone 4 mg
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 4 mg in 2 mls
Study: NCT02818491
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.5% 20 mls
Study: NCT02730208
Drug: Tezacaftor/Ivacaftor
Normalized name: ELEXACAFTOR/TEZACAFTOR/IVACAFTOR 100-50-75MG/75MG PKT,14
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
Study: NCT02730208
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IVA 150 mg tablet.
Study: NCT00468767
Drug: Vernakalant Injection 20 mg/mL
DrugBank: Vernakalant (DB06217)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01158703
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 75mg daily by mouth daily for 12 months
Study: NCT01158703
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill by mouth daily for 12 months
Study: NCT01158703
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
Study: NCT02789332
Drug: EC
Normalized name: DHEC
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
Study: NCT00626054
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
Study: NCT02859961
Drug: PRO 140 (350 mg)
Normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PRO 140 350 mg (175 mg/mL) SC injection per week
Study: NCT02859961
Drug: PRO 140 (525 mg)
Normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PRO 140 525 mg (175 mg/mL) SC injection per week
Study: NCT02859961
Drug: PRO 140 (700 mg)
Normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PRO 140 700 mg (175 mg/mL) SC injection per week
Study: NCT02310646
Drug: LEO 90100 Aerosol Foam
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
Study: NCT01902134
Drug: Tramadol-single dose
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol single oral dose (first 8 hours)
Study: NCT01902134
Drug: Tramadol-multiple doses
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Study: NCT02543086
Drug: Piperaquine Phosphate
Normalized name: Piperaquine phosphate
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
Study: NCT02060552
Drug: Diacerein
Normalized name: diacerein
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of IL-1βinhibitory
Study: NCT02060552
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control
Study: NCT02060552
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
Study: NCT04951232
Drug: Cinepazide Maleate
Normalized name: cinepazide maleate
DrugBank: Cinepazide (DB12123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
Study: NCT03534323
Drug: Duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
Study: NCT02653027
Drug: Lumacaftor-ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
Study: NCT03534323
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
Study: NCT00343811
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00151853
Drug: PPSB-SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01454245
Drug: JNJ-39439335
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
Study: NCT01454245
Drug: JNJ-39439335
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.
Study: NCT00371007
Drug: MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03627195
Drug: DSP-1349M
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DSP-1349M injectable
Study: NCT01808014
Drug: nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
Study: NCT04095390
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT04095390
Drug: SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mg
Study: NCT04095390
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg
Study: NCT03877237
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Study: NCT02391883
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02523040
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04564742
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg tablets given once daily, per oral use
Study: NCT03372083
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.